2024-512880-30-00已完成3 期
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 475
- 试验地点
- 61
- 主要终点
- Mean change from Baseline to Week 52 in Early Treatment Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) letters.
研究概览
简要总结
To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 2.0 mg aflibercept, in participants with neovascular AMD
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Male or female participants at least 50 years of age.
- •Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
- •An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
排除标准
- •Study Eye • Any previous treatment for neovascular AMD.
- •Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
结局指标
主要结局
Mean change from Baseline to Week 52 in Early Treatment Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) letters.
Mean change from Baseline to Week 52 in Early Treatment Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) letters.
次要结局
- Efficacy: - Proportion of participants gaining 15 or more ETDRS BCVA letters from Baseline to Week 52 - Proportion of participants gaining 10 or more ETDRS BCVA letters from Baseline to Week 52
- - Change in CNV area by fluorescein angiography (FA) from Baseline to Week 52 - Proportion of participants with absence of both SRF and IR cysts by spectral domain optical coherence tomography (SD-OCT) at Week 52
研究者
Clinical Trial Information
Scientific
Opthea Limited
研究点 (61)
Loading locations...
相似试验
已完成
2 期
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMDNeovascular Age-related Macular DegenerationNCT03345082Opthea Limited366
已完成
3 期
Clinical study to evaluate the handling and safety of AVT06 PFS in subjects with chorioretinal vascular disease (ALVOEYE-D).2023-505225-13-00Alvotech Swiss AG23
招募中
2 期
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior UveitisNCT07285070Novaliq GmbH20
招募中
2 期
A study to test whether BI 1815368 helps people with an eye condition called diabetic macular edema2024-520384-14-00Boehringer Ingelheim International GmbH193
进行中（未招募）
1 期
A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneratioeovascular age-related macular degeneration (wet AMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2017-002698-20-ITOPTHEA LIMITED366